Innate Pharma Presents TELLOMAK Phase 2 Study Data in Patients with Cutaneous T Cell Lymphoma
DENVER, Colo., Dec 09, 2024 (247marketnews.com)- Innate Pharma (NASDAQ: IPHA) presented new data featuring the quality-of-life improvements observed in patients with cutaneous T-cell lymphoma (CTCL) treated with lacutamab, in the TELLOMAK Phase 2 clinical study, at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, California.
TELLOMAK’s findings indicate that lacutamab may help alleviate some of the most distressing CTCL symptoms; currently, patients with relapsed or refractory CTCL have limited treatment options and regularly report lower health-related quality of life, especially when in advanced stages.
Dr Pierluigi Porcu, Director, Division of Medical Oncology and Hematopoietic Stem Cell Transplantation Thomas Jefferson University, and principal investigator in the TELLOMAK study, stated, “These findings underscore the potential of lacutamab for patients with advanced CTCL, particularly Sézary syndrome and mycosis fungoides, who face severe symptoms and limited treatment options. The promising results, including sustained itch reduction and improved skin symptoms, offer hope for enhancing quality of life. We are excited about lacutamab’s potential to bring meaningful relief to patients enduring this challenging disease.”
Dr Sonia Quaratino, Innate Pharma’s Chief Medical Officer, added, “We are encouraged by the data showing that lacutamab may help alleviate some of the most distressing symptoms of cutaneous T cell lymphomas. We remain committed to bringing lacutamab to patients in need and we remain focused on exploring all pathways forward to ensure this potential treatment reaches those who could benefit from it. Our dedication to addressing the unmet needs of patients continues to drive our efforts.”
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com